A negative association between IL-18 and TRAIL, but not IL-6, was identified with CAD [23], and colchicine anti-inflammatory treatment increased plasma TRAIL levels in these patients [61], supporting TRAIL’s anti-inflammatory role. This evidence concerns the gene IL18 and coronary artery disorder.